Selected research
Industry Research
Edaravone Industry Research Report 2026
Market perspective
The global Edaravone market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Edaravone is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Edaravone is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Edaravone is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Edaravone include Mitsubishi Tanabe Pharma, Piramal Healthcare, Simcere, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd., UCB India Ltd and Unichem Laboratories Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Edaravone market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Edaravone Market by Company
Mitsubishi Tanabe Pharma
Piramal Healthcare
Simcere
Sun Pharmaceutical Industries Ltd.
Taj Pharmaceuticals Ltd.
UCB India Ltd
Unichem Laboratories Ltd
Edaravone Segment by Type
Oral Edaravone
Injection Edaravone
Edaravone Segment by Application
Hospital
Clinic
Others
Edaravone Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Edaravone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Edaravone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Edaravone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Edaravone manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Edaravone by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Edaravone in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Edaravone
- Injection Edaravone
Applications
- Hospital
- Clinic
- Others
Companies covered
- Mitsubishi Tanabe Pharma
- Piramal Healthcare
- Simcere
- Sun Pharmaceutical Industries Ltd.
- Taj Pharmaceuticals Ltd.
- UCB India Ltd
- Unichem Laboratories Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Edaravone Market Size (2021-2032)
- 2.2.2 Global Edaravone Sales (2021-2032)
- 2.2.3 Global Edaravone Market Average Price (2021-2032)
- 2.3 Edaravone by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Edaravone
- 2.3.3 Injection Edaravone
- 2.4 Edaravone by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Edaravone Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Edaravone Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Edaravone Revenue of Manufacturers (2021-2026)
- 3.4 Global Edaravone Average Price by Manufacturers (2021-2026)
- 3.5 Global Edaravone Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Edaravone, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Edaravone, Product Type & Application
- 3.8 Global Manufacturers of Edaravone, Established Date
- 3.9 Global Edaravone Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mitsubishi Tanabe Pharma
- 4.1.1 Mitsubishi Tanabe Pharma Company Information
- 4.1.2 Mitsubishi Tanabe Pharma Business Overview
- 4.1.3 Mitsubishi Tanabe Pharma Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mitsubishi Tanabe Pharma Edaravone Product Portfolio
- 4.1.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.2 Piramal Healthcare
- 4.2.1 Piramal Healthcare Company Information
- 4.2.2 Piramal Healthcare Business Overview
- 4.2.3 Piramal Healthcare Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Piramal Healthcare Edaravone Product Portfolio
- 4.2.5 Piramal Healthcare Recent Developments
- 4.3 Simcere
- 4.3.1 Simcere Company Information
- 4.3.2 Simcere Business Overview
- 4.3.3 Simcere Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Simcere Edaravone Product Portfolio
- 4.3.5 Simcere Recent Developments
- 4.4 Sun Pharmaceutical Industries Ltd.
- 4.4.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.4.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.4.3 Sun Pharmaceutical Industries Ltd. Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharmaceutical Industries Ltd. Edaravone Product Portfolio
- 4.4.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.5 Taj Pharmaceuticals Ltd.
- 4.5.1 Taj Pharmaceuticals Ltd. Company Information
- 4.5.2 Taj Pharmaceuticals Ltd. Business Overview
- 4.5.3 Taj Pharmaceuticals Ltd. Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Taj Pharmaceuticals Ltd. Edaravone Product Portfolio
- 4.5.5 Taj Pharmaceuticals Ltd. Recent Developments
- 4.6 UCB India Ltd
- 4.6.1 UCB India Ltd Company Information
- 4.6.2 UCB India Ltd Business Overview
- 4.6.3 UCB India Ltd Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 UCB India Ltd Edaravone Product Portfolio
- 4.6.5 UCB India Ltd Recent Developments
- 4.7 Unichem Laboratories Ltd
- 4.7.1 Unichem Laboratories Ltd Company Information
- 4.7.2 Unichem Laboratories Ltd Business Overview
- 4.7.3 Unichem Laboratories Ltd Edaravone Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Unichem Laboratories Ltd Edaravone Product Portfolio
- 4.7.5 Unichem Laboratories Ltd Recent Developments
5 Global Edaravone Market Scenario by Region
- 5.1 Global Edaravone Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Edaravone Sales by Region: 2021-2032
- 5.2.1 Global Edaravone Sales by Region: 2021-2026
- 5.2.2 Global Edaravone Sales by Region: 2027-2032
- 5.3 Global Edaravone Revenue by Region: 2021-2032
- 5.3.1 Global Edaravone Revenue by Region: 2021-2026
- 5.3.2 Global Edaravone Revenue by Region: 2027-2032
- 5.4 North America Edaravone Market Facts & Figures by Country
- 5.4.1 North America Edaravone Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Edaravone Sales by Country (2021-2032)
- 5.4.3 North America Edaravone Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Edaravone Market Facts & Figures by Country
- 5.5.1 Europe Edaravone Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Edaravone Sales by Country (2021-2032)
- 5.5.3 Europe Edaravone Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Edaravone Market Facts & Figures by Country
- 5.6.1 Asia Pacific Edaravone Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Edaravone Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Edaravone Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Edaravone Market Facts & Figures by Country
- 5.7.1 South America Edaravone Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Edaravone Sales by Country (2021-2032)
- 5.7.3 South America Edaravone Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Edaravone Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Edaravone Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Edaravone Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Edaravone Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Edaravone Sales by Type (2021-2032)
- 6.1.1 Global Edaravone Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Edaravone Sales Market Share by Type (2021-2032)
- 6.2 Global Edaravone Revenue by Type (2021-2032)
- 6.2.1 Global Edaravone Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Edaravone Revenue Market Share by Type (2021-2032)
- 6.3 Global Edaravone Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Edaravone Sales by Application (2021-2032)
- 7.1.1 Global Edaravone Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Edaravone Sales Market Share by Application (2021-2032)
- 7.2 Global Edaravone Revenue by Application (2021-2032)
- 7.2.1 Global Edaravone Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Edaravone Revenue Market Share by Application (2021-2032)
- 7.3 Global Edaravone Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Edaravone Value Chain Analysis
- 8.1.1 Edaravone Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Edaravone Production Mode & Process
- 8.2 Edaravone Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Edaravone Distributors
- 8.2.3 Edaravone Customers
9 Global Edaravone Analyzing Market Dynamics
- 9.1 Edaravone Industry Trends
- 9.2 Edaravone Industry Drivers
- 9.3 Edaravone Industry Opportunities and Challenges
- 9.4 Edaravone Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst